251. Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
- Author
-
Dongliang, Bian, Siming, Jiang, Yicheng, Xiong, Mengfan, Qi, Jiawei, Wu, Alfredo, Addeo, Yoshikane, Yamauchi, Farkhad, Manapov, Wolfram C M, Dempke, Jacopo, Vannucci, Alessandro, Di Federico, Xiaoxiong, Xu, and Linsong, Chen
- Subjects
surgery ,small cell lung cancer (SCLC) ,limited disease ,neoadjuvant chemotherapy (NAC) ,Oncology - Abstract
The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed by surgery for IIIA-SCLC.Between 2004 and 2015, we reviewed 2,199 chemotherapy-treated stage IIIA (N1/2) SCLC cases in the Surveillance, Epidemiology, and End Results (SEER) database, and 32 NAC + intentional radical resection-treated, centrally-located IIIA-SCLC cases at Shanghai Pulmonary Hospital (SPH). Outcomes were compared between surgically and non-surgically treated patients from the SEER database after propensity score matching (PSM), and comparing lobectomy/bi-lobectomy and pneumonectomy patients from SPH. Prognostic factors were evaluated by Kaplan-Meier method and the Cox proportional hazards regression model.There was significantly higher overall survival (OS) in surgically treated IIIA-SCLC patients (OS, 44.8For stage IIIA SCLC patients, complete resection combined with chemotherapy might improve the prognosis than patients without surgery. Post-NAC lobectomy was not found to be superior to sub-lobectomy, while pneumonectomy was considered suitable for central-type IIIA-SCLC patients after NAC treatment.
- Published
- 2022
- Full Text
- View/download PDF